Drugs / TSHA-105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07102524 | Jul 2026 → Dec 2030 expected | developmental and epileptic encephalopathy, 25 | TESS Research Foundation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2021-12-06 | Taysha Gene Therapies, Inc. | Results Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency tayshagtx.com ↗
TSHA-105 normalized electroencephalogram (EEG) and citrate levels and improved survival in both early treated juvenile and later treated adult preclinical mouse models of SLC13A5 deficiency |
| 2021-08-25 | Taysha Gene Therapies, Inc. | Regulatory Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission tayshagtx.com ↗
today announced that it has been granted orphan drug designation from the European Commission for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. |
| 2021-05-11 | Taysha Gene Therapies, Inc. | Results Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update tayshagtx.com ↗
TSHA-105 significantly reduced plasma citrate levels, normalized EEG brain activity, and reduced the number of seizures and seizure susceptibility in SLC13A5 knockout mice |
| 2021-05-05 | Taysha Gene Therapies, Inc. | Results Taysha Gene Therapies Announces Multiple Data Presentations and Workshop Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy tayshagtx.com ↗
TSHA-105 significantly reduced plasma citrate levels, normalized EEG brain activity, and reduced the number of seizures and seizure susceptibility in SLC13A5 knockout mice |
| 2021-04-14 | Taysha Gene Therapies, Inc. | Results Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Day tayshagtx.com ↗
TSHA-105 significantly reduced plasma citrate levels, normalized EEG brain activity, and reduced the number of seizures and seizure susceptibility in SLC13A5 knockout mice |
| 2021-01-19 | Taysha Gene Therapies, Inc. | Regulatory Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency tayshagtx.com ↗
today announced that it has received both rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration (FDA) for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSHA-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07102524 ↗ |
| Action | Restore | “expresses the fully functional form of SLC13A5” NCT07102524 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV9-based gene therapy vector” NCT07102524 ↗ |
| Route | Intrathecal | “delivered intrathecally” NCT07102524 ↗ |
| Target | SLC13A5 | “expresses the fully functional form of SLC13A5” NCT07102524 ↗ |